Study type: Human research · Status: Verified against declared source
Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials
2021
Study scale: To resolve the reported discrepancies between studies evaluating the safety of Cerebrolysin after acute ischemic stroke, the present meta-analysis aimed to include a maximum number of RCTs and patients, and to fill existing safety information gaps by following-up with primary source references and requesting additional material from original authors and the producer of Cerebrolysin.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
The concepts of neuroprotection and neurorecovery after stroke have been researched in many clinical settings in the past decades, with the aim of deciphering the specific biological interplay between various pharmacological interventions and the post-lesion endogenous defense mechanisms.
Methods
We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling existing safety information gaps and inconsistent results.
Scale or participants
To resolve the reported discrepancies between studies evaluating the safety of Cerebrolysin after acute ischemic stroke, the present meta-analysis aimed to include a maximum number of RCTs and patients, and to fill existing safety information gaps by following-up with primary source references and requesting additional material from original authors and the producer of Cerebrolysin.
Key findings
We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling existing safety information gaps and inconsistent results.
Limitations and uncertainty
This study aimed to systematically assess safety outcomes for patients who received Cerebrolysin for ischemic stroke in randomized, double-blind, placebo-controlled, clinical studies.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.